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Abstract
Antibody-dependent enhancement (ADE) of dengue virus (DENV) 
infection is believed to play an important role in dengue-induced severe 
disease. Recent studies unraveled that both mature and immature DENV 
particles contribute to ADE. To understand how antibodies influence the 
fate of DENV particles, we explored the cell entry pathway of DENV 
with and without antibodies in macrophage-like cells. We showed that 
Ab-DENV predominantly enters through a phagocytosis-like pathway 
that involves a novel mechanism of initial virus-cell contact. This contact 
was facilitated by actin-mediated membrane protrusions that 1) engulf 
particles already bound to the cell, 2) capture virus particles localized 
away from the cell body, and 3) mediate virus uptake by non-directed 
ruffling of the cell membrane. Fusion was seen within Rab7 organelles. 
Overall, similar results were observed for standard and immature DENV 
preparations. Collectively, our findings suggest an unknown antibody-
mediated mechanism that controls the cell entry pathway of DENV in 
macrophages.




Dengue is the most common arthropod-borne viral infection in humans. There are 
five dengue virus serotypes (DENV1-5) and these cause around 390 million human 
infections worldwide each year1, 2. Approximately 500,000 to 1,000,000 individuals 
develop severe disease, presenting symptoms like plasma leakage, fluid accumulation, 
respiratory distress, severe bleeding, and organ impairment3, 4. Intriguingly, severe 
dengue is predominantly seen during primary infection in infants born to dengue-
immune mothers and in individuals experiencing a heterologous secondary DENV 
infection5-8. These observations indicate that pre-existing antibodies are a risk factor 
for severe disease and led to the well-known hypothesis of antibody-dependent 
enhancement (ADE) of DENV infection7, 9-11. It is hypothesized that pre-existing 
cross-reactive DENV antibodies positively influence the infectious properties of the 
virus7, 10. As a consequence, the total infected cell mass increases and this triggers 
an imbalanced immune response leading to severe disease10. It is, however, not 
completely understood how the antibodies influence DENV infectivity. 
DENV infectivity is mediated by the envelope (E) glycoprotein and involves 
three important steps: receptor binding, internalization into the host cell and 
membrane fusion12, 13. In the absence of antibodies, DENV E can bind to the cell 
by interacting with a wide range of receptor molecules, like DC-SIGN14 or sulfated 
glycosaminoglycans (GAGs)15. Upon virus-receptor binding, DENV particles are 
predominantly internalized into the cell via clathrin-mediated endocytosis16-18. 
Membrane fusion typically occurs from within late endosomes, where low pH and 
anionic lipids trigger conformational changes in the E glycoprotein to mediate 
membrane fusion16, 19. DENV infects a variety of human cells, but cells of the 
monocyte lineage, like macrophages and dendritic cells, are considered the major 
target cells for DENV replication10, 20.
DENV infectivity is controlled by the viral precursor membrane protein 
(prM)21-24. Within infected cells, prM has been shown to stabilize the E protein 
thereby preventing premature conformational changes within E during transit 
through the acidic Trans-Golgi network (TGN)21. Prior to the release of progeny 
virions, prM is cleaved into M and a pr peptide. DENV-infected cells are, however, 
known to secrete a very heterogeneous population of particles, ranging from mature 
M-containing viruses to fully immature prM-containing viruses23. Mature virions are 
considered to represent the infectious form of the virus. Fully immature particles, on 
the other hand, are essentially non-infectious in cells21, 22. Indeed, structural studies 
revealed that the pr peptide covers the E glycoprotein, thereby preventing binding 
and entry of immature virions into cells25, 26. The threshold of prM cleavage that is 
required for infectivity is currently unknown. 
Interestingly, antibodies have been observed to stimulate infectivity of both 
mature and immature virions, indicating that all particles are likely to contribute to 




falls below the threshold required for virus neutralization33. During infection, 
DENV-antibody complexes are targeted to Fc-γ-receptor (FcγR) bearing cells. The 
antibody-FcγR interaction subsequently facilitates a more efficient binding and 
internalization of the virus into the cell34, 35. Indeed, the role of FcγRs in ADE has 
been confirmed in vitro and in vivo29, 32, 36, 37. Furthermore, the infectivity of antibody-
opsonized immature DENV was found to be dependent on cellular furin activity, 
suggesting that immature virions mature upon virus entry29. An early study suggested 
that antibody-opsonized virions enter the cell via phagocytosis34. This was based on 
the observation that the internalization rate of antibody-opsonized virions resembled 
the rate of phagocytosis in macrophages28, 34. However, no details are known about 
the exact cell entry route of antibody-opsonized DENV in FcγR-bearing cells.
In this study, we unraveled how antibodies influence the cell entry pathway 
of DENV particles, thereby increasing our knowledge on the phenomenon of ADE. 
The route of DENV entry in the absence and presence of antibodies was analyzed 
in macrophages by (i) studying the dynamics of viral entry with single-particle 
tracking, (ii) examining the effect of a variety of endocytic chemical inhibitors on 
viral fusion, (iii) imaging – in real time – the interaction of the actin cytoskeleton 
with fluorescently labeled single virus particles, and (iv) exploring the Ab-DENV 
intracellular pathway by using Rab mutants. Furthermore, to address the role of prM 
on virus cell entry, we used both antibody-opsonized mature and immature DENV 
particles.
Results
Dynamics of antibody-mediated DENV cell entry
 
Antibody-mediated cell entry of DENV was investigated by use of human 
monoclonal antibodies mAb 5 and mAb 3-147, which recognize the E and prM 
protein respectively30. Standard DENV (stdDENV) was produced on C6/36 
mosquito cells and immature DENV (prMDENV) was cultivated on furin-deficient 
LoVo cells22. The immature status of LoVo-derived DENV was confirmed by 
Western-blot analysis (22, data not shown). The PFU-to-particle ratio of prMDENV 
was 7 x 107 (± 2.5 x 107), which is 1,000,000 to 100,000-fold reduced compared 
to that of stdDENV. This is in line with previous studies22, 29 and shows that 
prMDENV is essentially non-infectious in cells. After the initial characterization 
of the virus preparations, we determined the enhancing profile of the mAbs on 
murine macrophage-like P388D1 cells. We used P388D1 cells since they express 
FcγRIII (CD16), FcγRII (CD32), and FcγRI (CD64)38, 39 and are known to support 
ADE of DENV32, 40-42. Murine FcγRs are considered to be structurally related to 
human FcγRs43, hence, human antibodies are recognized by P388D1 cells. Prior to 
infection, mAb5 was complexed to stdDENV and mAb-3-147 was incubated with 
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prMDENV. Maximum enhancement of stdDENV infection (2 log10 increase in 
titers compared to the positive control) was obtained at a mAb concentration of 40 
and 400 ng/mL (Fig. S1-A). In case of mAb 3-147, optimal ADE of prMDENV 
was reached at 0.1 ng/mL (Fig. S1-B). Furthermore, and in agreement with previous 
studies 22, we found that prMDENV is non-infectious in macrophage cells in the 
absence of antibodies (Fig. S1-B). Also, a considerable reduction of Ab-stdDENV 
(90% ± 3.7) and Ab-prMDENV (77.7% ± 1.2) infectivity was seen in cells treated 
with anti-CD16/CD32, confirming the importance of FcγRs in antibody-mediated 
cell entry (Fig. S1-C).
Then, we performed single virus tracking to investigate if antibodies influence 
the dynamics of viral entry. Single DENV particles were visualized by DiD labeling, 
as described before16. The infectivity of DiD-labeled DENV was comparable to that 
of unlabeled virus, indicating that the incorporation of the probe did not influence 
the functional properties of the virus (data not shown). 
Figure 1. Kinetics of antibody-opsonized DENV entry in macrophages. Single-particle tracking of 
DiD-labeled Ab-stdDENV, Ab-prMDENV and stdDENV was performed in P388D1 cells at 1 frame 
per second. (A) Cell image obtained with DIC optics showing a trajectory of a single DiD-labeled Ab-
stdDENV particle. The white star represents the membrane fusion site. Scale bar: 2 μm. (B) Snapshots 
of a DiD-labeled Ab-stdDENV particle at different time points post-infection. Membrane fusion is 
observed as a sudden increase in fluorescence intensity. The image was artificially modified to show the 
differences in fluorescence intensity, from low (purple) to high (yellow) intensity. (C) The percentage 
of fused virus particles calculated as a function of time. In total 35 trajectories were analyzed for Ab-
stdDENV, 37 for Ab-prMDENV, and 36 for stdDENV. The time point of membrane fusion was 




Upon DiD labeling, the virions were incubated with the previously defined 
enhancing concentrations of antibody and added to P388D1 cells. Subsequently, 
single-particle tracking of the DiD-labeled virus was performed at a time-lapse of 
1 frame per second (37°C). More than 50 movies were recorded. Figure 1A gives 
an example of a complete trajectory of an Ab-stdDENV particle in a P388D1 cell. 
Initially, this particle moves within the cell periphery, and then a rapid movement 
(likely on microtubules) is observed which is followed by intermitted movement 
prior to membrane fusion. The representative movie of this trajectory is uploaded 
as Movie S1. Quantification of the trafficking behavior was not possible as only a 
limited number of complete trajectories were recorded. In a large number of movies, 
parts of the trajectory are out of focus due to the thickness of macrophage cells. The 
specific time point of membrane fusion was defined as the moment when fluorescence 
intensity at least doubled. In the trajectory of Figure 1B, fusion is seen at 393 seconds 
post-addition of the stdDENV-immune complex to the cell. Quantitative analysis 
revealed a considerable delay in the fusion time point of Ab-prMDENV with respect 
to Ab-stdDENV and stdDENV (Fig. 1C). As illustrated in Figure 1C, 50% of the 
Ab-prMDENV particles have fused within 24 min. On the other hand, however, 
50% fusion of Ab-stdDENV particles was seen at 10 min, which indicates that prM 
influences the dynamics of viral entry. Furthermore, an intermediate time point (13 
min) of fusion was detected for stdDENV in the absence of antibodies. 
Analyzing DENV cell entry by chemical inhibitors
The differences in fusion time points may reflect the usage of different 
entry pathways. This prompted us to further evaluate the cell entry pathway 
of DENV in the absence and presence of antibodies. To define the cell entry 
pathway, various perturbants of endocytic pathways were added to the cells. The 
concentration of the chemical inhibitors used was defined based on successful 
inhibition of entry of known fluorescently labeled cargo controls, like transferrin, 
dextran and cholera toxin B (see Fig. S2). The effect of the compound on DENV 
cell entry was measured by use of a fluorescence microscopy-based fusion 
assay. We have used this assay before and quantified viral internalization by 
measuring the extent of fusion of DiD-labeled virus44. Interestingly, as can also 
be deduced from Figure 2A (left column upper and bottom image), enhanced 
DENV membrane fusion activity is seen in presence of enhancing concentration 
of antibodies. Subsequent quantification of the fluorescence intensity of 15 
randomly selected images derived from three independent experiments revealed 
that membrane fusion activity of Ab-stdDENV is 6-fold increased compared to 
that of stdDENV. This indicates that ADE indeed involves enhanced cell entry 
and/or membrane fusion of DENV particles. 
To further validate the assay used, cells were infected in presence of FcγR 
blocker or ammonium chloride (NH4Cl), a compound known to neutralize 
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the pH of intracellular compartments. As seen in Figure 2, the FcγR blocker 
markedly reduced the membrane fusion capacity of DiD-labeled stdDENV and 
prMDENV particles in the presence of enhancing concentrations of antibodies. 
These observations are in line with the results obtained in the titration assay and 
confirm that antibody-mediated entry of DENV in P388D1 cells is mediated by 
FcγRs. As expected, no membrane fusion was seen in cells treated with NH4Cl 
(Fig. 2A-C). All of the above results are in line with the literature29, 34, 45 and 
demonstrate that the microscope assay can be used to evaluate the route of 
antibody-mediated DENV cell entry. 
Figure 2. Antibody-opsonized DENV entry inhibition by endocytic inhibitors. DiD-labeled DENV 
(opsonized and non-opsonized) was added in situ to P388D1 cells in the presence or absence of the 
indicated inhibitors. After 30 min of infection at 37°C, the cells were washed and snapshots were taken 
with an oil-immersion 100x objective. (A-C) Representative images upon DiD-DENV infection with 
and without prior treatment of the cells with NH4Cl (50 mM) and FcR blocker are shown. Scale bar: 25 μm. Fusion inhibition was calculated by analyzing the total extent of membrane fusion of DiD-
labeled virus with ImageJ. (D-F) Representative images of a fusion assay performed in P388D1 cells 
electroporated with Eps15-GFP (empty vector D3Δ2 (control) and DNM (E95/295)). Scale bar: 7 
μm. (G-I) Fusion inhibition of different biochemical inhibitors with an end concentration of 50 μM 
nystatin, 150 μM dynasore, 15 μM cytochalasine B, 1 μM latrunculin, 2 μM wortmannin, or 250 μM 
NSC23766 was used. The percentage of fusion inhibition was calculated with respect to the non-treated 
control. The average of at least three independent experiments is shown ± SEM.
We started to investigate the route of cell entry by examining the role of 




dominant negative mutant (DNM) of Eps15 (E95/295), a protein required for 
clathrin-dependent uptake46. As seen in Figure 2D-F, the Eps15-DNM inhibited 
fusion in all three infection conditions, albeit to a different extent. The most extensive 
inhibition (>80%) was seen following infection with stdDENV in the absence 
of antibodies (Fig. 2F and I). These results point towards a role of the clathrin 
machinery in entry of DENV and antibody-bound DENV. Treatment of cells with 
nystatin, a cholesterol binding agent, leads to a complete ablation of morphologically 
identifiable caveolae47. We observed that nystatin treatment had no influence on 
stdDENV, Ab-stdDENV or Ab-prMDENV fusion (Fig. 2G-I), which suggests 
that entry of DENV with and without Abs is caveolae-independent. 
 Thereafter, the role of dynamin and actin was measured. Dynamin, a 
small GTPase, has a critical role in endocytic membrane fission events48. Actin is 
important in numerous endocytic pathways, like clathrin-mediated endocytosis49, 
macropinocytosis50, caveolae-mediated endocytosis51, and phagocytosis52. Though 
the actin cytoskeleton function is variable between distinct endocytic pathways53. 
Treatment of P388D1 cells with dynasore, a compound that interferes with 
the GTPase activity of dynamin1 and dynamin254, abolished membrane fusion 
activity of DENV irrespective of the maturation status and with and without prior 
opsonization with antibodies (Fig. 2G-I). Moreover, disruption of actin filaments 
with cytochalasin B and latrunculin was found to reduce fusion of Ab-stdDENV, 
Ab-prMDENV and stdDENV (Fig. 2G-I). Inhibition of PI3K, a key coordinator 
in actin remodeling, through wortmannin, also reduced membrane fusion activity 
of Ab-stdDENV and Ab-prMDENV (Fig. 2 G-I). However, inhibition of Rac1 
(NSC23766), a Rho GTPase involved in controlling actin cytoskeleton organization, 
blocked Ab-stdDENV but not Ab-prMDENV membrane fusion (Fig. 2G-H). 
Wortmannin and NSC23766 had little effect on stdDENV fusion (Fig. 2I). These 
results demonstrate that actin and the regulators of actin remodeling play a critical 
role during Ab-DENV endocytosis. The different response to PI3K inhibitors is 
consistent with a distinct DENV cell entry mechanism in the presence and absence 
of antibodies.
Ab-DENV activates extensive ruffling of the cell membrane via FcgRs
The actin cytoskeleton has been observed to support different processes 
related to endocytosis, like the invagination of membrane segments into the 
cytoplasm, elongation of invaginations, and protrusions in the form of filopodia and 
ruffles52, 55. In order to study how antibody-opsonized DENV particles interact with 
the actin cytoskeleton, we performed live-cell imaging in eYFP-actin expressing 
P388D1 cells. Interestingly, dramatic changes in cell morphology and actin 
redistribution were observed upon infection with DiD-labeled Ab-stdDENV and 
Ab-prMDENV (Fig. 3). Ab-stdDENV and Ab-prMDENV particles were not only 
seen at the cell surface (3A), but also associated with membrane ruffles (3B) and 
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filopodia-like structures (3C). Ruffles were observed across the cell membrane as 
sheet-like protrusive structures with a heterogeneous morphology (Fig. 3D). 
 
Figure 3. Ab-DENV induction of actin cytoskeleton rearrangement via FcgRs. DiD-labeled virus 
(Ab-stdDENV, Ab-prMDENV and stdDENV) was added to eYFPActin-expressing P388D1 cells. 
The cells were kept at 37°C for live-cell imaging with a spinning disk confocal microscope. Ab-DENV 
was observed to localize to the (A) cell membrane, (B) membrane ruffles and (C) actin filopodia 
during entry. Scale bar: 7 μm. (D) Time series of antibody-opsonized DENV induced cell membrane 
ruffling. The white arrowhead indicates the place where the ruffle starts. (E-I) Cell movement was 
quantified over time upon the indicated treatments. (E) Representative images of P388D1 cells under 
the indicated conditions are shown as the overlays of the cell body outlines of a time-lapse of 20 min. 
(F-I) The Movement ratio (MR) quantifies the extent of movement of one cell over a frame sequence. 
See Figure S3 for more details on how to calculate it. Based on the MR, the movement response was 
classified as Low (MR < 2), Intermediate (MR = 2-3) or Extensive (MR > 3). For each condition, 15 
cells were used for analysis. The gray area indicates the intermediate response. The proportion of cells 
showing Low, Intermediate, and Extensive response is indicated at the right corner of (E). 
The extensive actin-driven membrane ruffling is illustrated by Movies S2 
and S3. In the absence of any added stimuli (negative control), the eYFP-Actin 
expressing macrophages are constitutively active (as reported by 56), but do not show 
widespread ruffling of the membrane (Movie S4). Ruffling induced by Ab-stdDENV 
and Ab-prMDENV is initiated at 3 to 5 minutes post-infection (mpi) (Movies S5 
and S6). Movie S5 shows eYFP-Actin expressing cells during the first 4.5 minutes 
following infection with Ab-stdDENV. DiD-labeled particles are visible, but not yet 
bound to the cell membrane. A constitutive movement of the cell body can be seen. 
Movie S6 shows the same group of cells at 5 mpi. A widespread and highly active 




But what is triggering membrane ruffling? Is it the immune complex, the 
virus or the antibody? To address this issue, we first developed an ImageJ-based 
method to quantify the extent of cell ruffling in one cell. With this method, we 
calculated the “Movement ratio” (MR) by dividing the “total area” covered by a 
moving cell for the whole sequence, with respect to the smallest surface area occupied 
by the same cell in the same time series (explained in detail in Fig. S3). Based on 
the resulting Movement ratio, cells were classified in three groups: Low (MR < 2), 
Intermediate (MR = 2-3), and Extensive (MR > 3). To visually illustrate the results, 
the projections of the cell body outlines of a time-lapse of 20 min are shown in 
Figure 3E. No differences were observed between the ruffling response activated by 
Ab-stdDENV (Movie S2) and Ab-prMDENV (Movie S3). Extensive membrane 
ruffling is observed in approximately 50% of the cells infected with Ab-stdDENV 
(47%) and Ab-prMDENV (53%) (Fig. 3E-F). Cells infected with stdDENV and 
prMDENV in the absence of antibodies predominantly show intermediate ruffling, 
31% and 53% respectively (Fig. 3E-F). Cytochalasin B prevented membrane ruffling 
in all conditions (MR < 2). The addition of soluble anti-E and anti-prM antibodies 
to the cells also induced membrane ruffling, albeit to a somewhat lower extent than 
antibody-opsonized DENV (Fig. 3G). Similar results were found upon addition 
of dengue patient immune serum and an IgG isotype antibody. Collectively, these 
results indicate that membrane ruffling is not caused by the virus but is triggered 
through the addition of antibodies to cells. 
These results prompted us to further study the role of antibodies in ruffling 
induction of the cell membrane. The use of a FcγR blocker (anti-CD16/CD32) 
prevented ruffling induced by Ab-stdDENV, Ab-prMDENV and by soluble anti-E 
mAbs (Fig. 3H). In addition, we observed that Fab fragments with and without prior 
opsonization to stdDENV and prMDENV particles do not induce extensive ruffling 
(Fig. 3I). Taken together, these results indicate that activation of membrane ruffling 
in macrophages by Ab-stdDENV and Ab-prMDENV is likely triggered through 
the interaction of the antibody with a FcγR expressed at the cell surface.
Ruffling involvement in Ab-DENV internalization
Ruffling, the involvement of actin, and the role of PI3K suggests that cell 
entry of antibody-opsonized DENV may take place via macropinocytosis, as has been 
recently shown for several other viruses (for reviews see 57 and 58). Macropinocytosis 
is an actin-dependent process characterized by the formation of macropinosomes, 
which are structures of eukaryotic plasma membranes ranging in size from 0.2 to 
10 μm that are used to engulf extracellular fluid for cellular uptake59. Indeed, upon 
infection with Ab-stdDENV and Ab-prMDENV, membrane ruffles were seen that 
close to form macropinosomes (Movies S7 and S8). In Figure 4A, a time series of 
the closure of a vesicle is presented. Actin accumulation is visible in the area of ruffle 
formation and in the newly formed macropinosome. 
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EIPA (100 μM) for 1 h at 37°C. Cells were infected with DiD-labeled Ab-stdDENV, Ab-prMDENV 
and stdDENV and analyzed as in Figure 2. (C) FcγR expression in eYFPActin-expressing cells. Scale 
bar: 10 μm.
Macropinosome formation requires Na+/H+ exchanger (NHE) activity to 
modulate Rho GTPases at the cytoplasmic membrane60. Inhibition of NHE activity 
by EIPA (an amiloride derivative), is often used to define the role of macropinocytosis 
in a specific process60. In our case, EIPA treatment indeed blocked Ab-stdDENV, 
Ab-prMDENV and stdDENV fusion in P388D1 cells (Fig. 4B). However, caution 
should be taken because NHEs can also be found in the membrane of other 
intracellular vesicles61, thereby potentially interfering with other pH-dependent 
endocytic pathways as well.
 Taken together, our findings indicate that antibodies induce macropinocytosis 
over a large fraction of the cellular plasma membrane by extensive actin-mediated 
ruffle formation. As the consequence of this cell-wide activation, viral particles may 
be internalized through macropinosomes58. Since antibody-mediated entry of DENV 
is facilitated through interaction with FcγRs, we wondered whether we could detect 
these receptors in ruffles. Figure 4C shows that FcγRs are widely expressed on ruffles 
induced by Ab-stdDENV, thereby potentially explaining the mechanism of binding 
and uptake through macropinocytosis. However, uptake through macropinocytosis 
appears to be rather inefficient as only a few macropinosomes contained visible Ab-
stdDENV (4 out of 50) or Ab-prMDENV (2 out of 50) complexes.
Ab-opsonized DENV is internalized by actin cell-surface protrusions 
Given the inefficient uptake of virus particles by macropinocytosis, we 




Indeed, upon further analysis of the recorded movies, we also observed viral uptake 
through localized cell-surface actin protrusions (Fig. 5). These were not considered 
as part of the ruffling response described in the previous section, since ruffling was 
observed as a general response of the complete cell body and these protrusions 
represent localized reactions to a viral particle.
We observed two distinct types of localized actin-mediated uptake of Ab-
DENV. Type 1 implies uptake through actin protrusions that are formed upon direct 
virus-cell contact (Fig. 5A). In case of Type 2, actin protrusions were generated 
towards viral particles located away from the cell body. Once the actin-mediated 
structure reached the virus particle, the filopodia retracts and pulls back the virion to 
the cell membrane (Fig. 5C and Movie S9). 
To evaluate the efficiency of these processes we quantified the number of 
events by visual examination. Type 1 and Type 2 virus-cell interactions were counted 
in 73 cells per condition and classified as successful or unsuccessful, based on the 
ability of the actin protrusion to mediate viral uptake. In total, 60 events (including 
both Type 1 and 2) were recorded for Ab-stdDENV, 31 events for Ab-prMDENV, 
and 29 events for stdDENV. Representative examples are shown in Figure 5A-D. 
Figure 5A shows a successful Type I uptake. The antibody-opsonized DiD-labeled 
particle is bound to the plasma membrane. At 2.6 mpi, an actin protrusion starts 
to surround the virus particle and subsequently captures it. Figure 5B shows an 
unsuccessful Type 1 uptake. This particle is surrounded by actin protrusions but did 
not end up inside a cellular compartment. A successful Type 2 uptake is illustrated 
in Figure 5C. Initially, an antibody-opsonized virus is seen approximately 5 μm away 
from the cell body. Then, a filopodia-like structure protrudes and elongates in the 
direction of the virus particle. This protrusion reaches and binds to the viral particle, 
and pulls it back to the cell body. The complete process lasts 54 seconds. This is 
also visible in Movie S9. Figure 5D presents an unsuccessful Type 2 uptake. Here, 
actin protrusions are directed towards the virion but fail to pull it back. Since we 
observed Type 2 taking place multiple times against the same particle (Movie S10), 
we believe that Type 2 movement represents a specific direct process to capture virus 
particles from the extracellular environment. In all conditions, Type 1 appears to be 
more efficient than Type 2 (Fig. 5E-G). The frequency of successful Type 1 uptake 
is similar for Ab-stdDENV, Ab-prMDENV and stdDENV (Fig. 5E-G). Successful 
Type 2 uptake was seen in 8 out of 36 (22%) events for Ab-stDENV and 4 out of 11 
(36%) for Ab-prMDENV (Fig. 5E-F). 
Type 2 is, however, a remarkable phenomenon that seems to play an 
active role in antibody-mediated uptake. As observed in Figure 5C, Type 2 uptake 
is directed specifically against a single virus particle that is not moving and not 
associated with the plasma membrane or any other visible actin structure. But how 
is the cell able to sense the presence and position of the virus without having contact 
with it? Or is the membrane surface area of the cells wider than seen by eYFP-actin? 
To address this issue, we stained the membranes of eYFP-Actin expressing cells with 
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the lipophilic probe DiD and used high resolution differential interference contrast 
(DIC) microscopy to evaluate the membrane surface area of the cells. The DiD 
signal completely overlaps with eYFP-actin, indicating that all cellular structures 
are detected with eYFP-Actin (Fig. S4). At this moment we do not know how cells 
sense the virions. Interestingly, though, Type 2 interactions were only observed in 
case of antibody-opsonized stdDENV and prMDENV and not in the absence of 
antibodies (Fig. 5G). 
Figure 5. Ab-DENV uptake is mediated by actin protrusions. The experimental set-up is similar as 
described in the legend to Figure 3. (A-D) Representative montages of alternating time-lapse exposures 
of DiD-DENV and eYFPActin during entry. (A-B) Type 1 virus uptake. (C-D) Type 2 virus uptake. 
DiD-virus is shown in red. eYFPActin expressing cells are shown in green. White arrowheads point out 
single viral particles associated with actin structures. (E-G) Frequency of Type 1 and type 2 uptake in 




Endocytic trafficking of antibody-opsonized DENV
After uptake and internalization, most viruses traffic through intracellular 
vesicles till a compartment is reached where membrane fusion occurs (refer to 62 
for an extensive review). The intracellular compartments hijacked by viruses can 
be endosomes, phagosomes or pinosomes, all of which have been described to 
undergo acidification and a maturation process that involves the gain and loss 
of early/late markers before fusion with lysosomes57, 63, 64. Since trafficking of the 
different intracellular compartments is controlled by Rab GTPases65, we used a set 
of fluorescently-labeled Rab dominant-negative mutants (DNM) to analyze which 
of these GTPases is required for viral transport. Fluorescently labeled dextran was 
used as a control to evaluate the activity of the DNMs. Fig. S2 shows that the 
overexpression of Rab5 and Rab7 DNMs inhibited uptake of the fluorescently-
labeled dextran. DENV membrane fusion activity was reduced in cells transfected 
with DNM of Rab7 for all experimental conditions (Fig. 6A-C), particularly in the 
case of stdDENV in the absence of antibodies (88% of inhibition with respect to the 
WT Rab7). Interestingly, Rab5 was required for Ab-DENV fusion (black bars, Fig. 
6D-F), but not for stdDENV. 
Figure 6. Effect of Rab5 and Rab7 
dominant-negative mutants 
in fusion of Ab-DENV. DiD-
labeled DENV (with and without 
antibodies) was added in situ 
to P388D1 cells electroporated 
with the indicated plasmids. (A-
C) Representative examples of 
membrane fusion. Membrane 
fusion of DiD-labeled virus is 
observed as highly fluorescent 
red puncta in the WT and DNM 
electroporated cells. All plasmids 
have GFP as a reporter gene. Scale 
bar: 7 μm. (C) Quantification of 
the effect of the DNM proteins on 
viral fusion. For analysis, 85 cells 
positive for the expression of the 
plasmids were used. The percentage 
of inhibition was calculated with 
respect to the WT plasmid control. 




The study presented here aimed to understand how DENV enters macrophages in 
the absence and presence of antibodies. A model with our main findings on DENV 
entry is shown in Figure 7. In brief, actin rearrangements in the form of cell surface 
protrusions actively mediate internalization. For DENV infection in the absence 
of antibody, only Type 1 and 3 are observed. For antibody-opsonized stdDENV/
prMDENV, Types 1, 2 and 3 are seen. Engulfment occurs when the viral particles are 
enclosed by filopodia-like structures or membrane ruffles. Distinct entry pathways 
are used by DENV in the absence and presence of antibodies. Antibody-mediated 
entry was found to be FcγR, pH, clathrin, dynamin, actin, PI3K, Rab5, and Rab7-
dependent, but caveolae-independent. DENV cell entry in the absence of antibodies 
is pH, clathrin, dynamin, actin, and Rab7-dependent, but FcγR, caveolae, PI3K, and 
Rab5-independent. 
The biochemical signature of DENV entry in the absence of antibodies does 
not fit with a classical textbook view of one endocytic process. The importance of 
clathrin and dynamin is suggestive for entry via clathrin-mediated endocytosis46. The 
actin cytoskeleton is important in numerous endocytic and phagocytic processes, but 
the function of actin within these processes is different55. In classical clathrin-mediated 
endocytosis, actin supports the process of invagination of the membrane and helps 
with the elongation and scission of the new vesicle55. We, however, observed that actin 
forms active membrane protrusions that engulf the particles (Type 1), a phenomenon 
that has been linked to phagocytic processes66. Entry through phagocytosis seems 
unlikely, however, since PI3K is not required in DENV cell entry and this molecule 
is generally believed to be important for phagosomal maturation66, 67. Therefore, 
we propose that DENV entry in macrophages is via a novel mechanism involving 
elements of different entry pathways. Furthermore, enhanced membrane fusion was 
seen in Rab5-DNM expressing cells whereas a marked inhibition was noticed in 
Rab7-DNM cells. This suggests that DENV particles bypass Rab5 organelles and 
are immediately delivered to Rab7 compartments were membrane fusion occurs. 
Similar results were observed for lymphocytic choriomeningitis virus68.The authors 
suggested that this atypical transport behavior may serve to internalize plasma 
membrane molecules and bound ligands that need to avoid recycling regulated 
by Rab5 early endosomes68. The observation that DENV fuses from within Rab7 
compartments is in agreement with our earlier data16 and is in line with the described 
lipid dependence for DENV fusion19. 
The entry profile of antibody-opsonized DENV is similar to stdDENV entry 
except for the role of FcγRs and PI3K. On the basis of this difference we propose that 
antibody-opsonized DENV entry in macrophages occurs through a phagocytosis-
like pathway. Indeed, FcγRs66, dynamin69, active formation of actin protrusions52, 66, 
and PI3K70 have been linked to phagocytosis. We also observed involvement of the 




phagocytosis as different elements of the clathrin machinery, like AP-2, have been 
located in the outer layer of phagosomes and play a role in phagosomal maturation71, 
72. Phagocytosis-like entry may seem unexpected given the relatively small size of 
Ab-DENV complexes. Indeed, it is generally believed that phagocytosis is meant for 
uptake of particles larger than 0.5 μm66. Yet, phagocytosis-like pathways have been 
described for viruses with smaller dimensions, like Adenovirus type 2 (90-100 nm)73 
and HSV-1 (200 nm)74. Hence, the size of the particles is not the only determinant 
needed to trigger phagocytosis74. Upon phagocytosis, the antibody-opsonized particles 
traffic through Rab5 and Rab7 organelles and both early and late phagosomes are 
required for entry and membrane fusion in P388D1 macrophages. Given the pH and 
lipid requirements for fusion, we anticipate that the virus predominantly fuses from 
within late phagosomal compartments. 
A surprising novel finding was Type 2 uptake of antibody-opsonized 
stdDENV and prMDENV. To our knowledge, this is the first study that describes 
the possibility of a cell to actively search and capture a virus particle from the 
environment. But how is the cell able to detect virus particles located away from its 
main body? A possible explanation is chemotaxis. Antibodies are known to associate 
and dissociate from their antigen over time75. It is tempting to speculate that the 
dissociated antibodies leak away from the complex and serve as a chemotactic 
stimulus that macrophages can sense. Indeed, Type 2 uptake was not observed with 
stdDENV in the absence of antibodies. Thus, antibodies not only flag the virus as a 
foreign antigen that needs to be degraded, they may also induce an active capturing 
mechanism in macrophage cells. In this sense, Type 2 is a remarkable example of how 
viruses could utilize pathogen-sensing functions of macrophages.
Macropinocytosis may serve as a parallel entry pathway for both antibody-
opsonized and non-opsonized DENV into macrophages. Cell entry through 
macropinocytosis is reported for a growing number of viruses, like poxviruses, 
filoviruses, influenza A virus (IAV), adenovirus and human immunodeficiency virus 
(HIV)76-81. However, in the case of DENV, only very few viral particles were seen inside 
pinosomes, suggesting this is not the main route of entry. What then is the role of 
the extensive membrane ruffling that is observed following the addition of antibodies 
or Ab-DENV particles? Activation of extensive macropinocytosis in macrophages 
may be considered a host defense strategy as it (i) allows bulk internalization of 
nutrients from the environment, which would provide the cell the required energy to 
adequately respond to danger signals like foreign material or antibodies, (ii) avoids 
the silencing of inflammatory responses observed in some phagocytic-mediated 
processes, (iii) provides the macrophage with an alternative to clear large amounts of 
extracellular material, which cannot be done with phagocytosis. Simultaneously, the 
virus may take advantage of this phenomenon and use the enhanced nutrient uptake 
for virus replication. Indeed, macropinocytosis was observed to positively influence 
the multiplication of the bacteria Brucella abortus82.  
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Figure 7. Model of DENV entry into macrophages. The model illustrates the major steps involved 
in stdDENV, Ab-stdDENV, and Ab-prMDENV entry in macrophage-like cells. The fluorescence 
microscopy images provide examples for each step. For clarity purposes, only drawings with Ab-
opsonized stdDENV particles are shown. In brief, the infection of macrophage-like cells starts with (a) 
the association with membrane protrusions: Type 1, Ab-stdDENV directly binds to FcγRs at the cell 
membrane; Type 2, virus particles are detected by the cell and pulled back by membrane protrusions; 
Type 3, virions associate with membrane ruffles expressing FcγRs. All 3 modes of uptake are seen for 
Ab-stdDENV and Ab-prMDENV, whereas only Types 1 and 3 are observed for stdDENV in the 
absence of antibodies. It is as yet unknown which receptor facilitates Type 1 and 3 uptake following 
DENV infection in the absence of antibodies. (b) Engulfment occurs when Ab-DENV is surrounded 
by actin protrusions to form a phagocytic cup. In case of the macropinocytosis-like uptake, Ab-DENV 
is engulfed by ruffles that close to form a pinosome. (c) Trafficking of Ab-DENV takes place via Rab5 
compartments. The antibody-opsonized virus primarily fuses within Rab7 compartments. 
We observed that the fusion time point of DiD-labeled Ab-prMDENV 
particles is approximately two times delayed compared to Ab-stdDENV. This 
observation points to a distinct trafficking behavior of Ab-prMDENV particles 




dependent maturation process prior to membrane fusion29. It is known that progeny 
virions release the pr peptide upon secretion of the particle to the extracellular 
pH neutral milieu25. During infection, it is hypothesized that the lower pH of late 
phagosomal compartments –when compared to the luminal pH of vesicles within 
the Golgi apparatus– is sufficient to release the pr peptide from the virion26. Hence, 
we postulate that the additional time required to initiate membrane fusion reflects 
the processes involved in virion maturation. 
It is important to mention that an antibody-mediated entry pathway by itself 
does not entirely explain ADE. Under neutralizing conditions, virions will also enter 
macrophages via an antibody-mediated pathway. Indeed, FcγRs have been shown 
to be important in antibody-mediated neutralization as well as antibody-mediated 
enhancement of infection34, 41, 83, 84. Hence, it is likely that a similar entry pathway 
is used under neutralizing and enhancing conditions. What then determines the 
enhancing or neutralizing capacity of the antibody? We and others have suggested 
that ADE is controlled at the level of membrane fusion36, 85. Fusion and thus ADE 
may occur when antibodies dissociate from the virion during entry or bind with low 
occupancy thereby allowing unoccupied E proteins to undergo fusion. Furthermore, 
prM antibodies are likely to dissociate from the virion when the pr peptide is released 
and therefore these antibodies are preferentially linked to ADE. 
In conclusion, our results provide evidence for a novel antibody-mediated 
mechanism meant to regulate the uptake and internalization of DENV particles in 
macrophages. The overall pattern of Ab-stdDENV and Ab-prMDENV was similar, 
indicating that the antibody dictates the route of entry and not the virion. This data 
not only elucidates how antibodies alter the cell entry pathway of DENV particles 
in living macrophages, but also shows that Ab-virus complexes can take advantage 
of an active pathogen-sensing mechanism of macrophages. It would be interesting 
to establish whether the intervention of these entry pathways may be useful in the 
design of antiviral drugs that can be used in dengue severe disease. 
Experimental procedures
Cells and viruses
Murine macrophage P388D1 cells were maintained in DMEM (PAA) 
supplemented with 10% FBS, penicillin (100 U/mL), streptomycin (100 μg/mL), 
sodium bicarbonate (Invitrogen, 7.5% solution) and 1.0 mM sodium pyruvate (Gibco). 
Baby hamster kidney (BHK-15) cells were cultured in 1x high glucose, L-glutamine-
enriched DMEM with 10% FBS, penicillin (100 U/mL), and streptomycin (100 μg/
mL). Aedes albopictus C6/36 cells were maintained in MEM (Gibco) supplemented 
with 10% FBS, 25 mM HEPES, 7.5% sodium bicarbonate, penicillin (100 U/mL), 
streptomycin (100 μg/mL), 200 mM glutamine and 100 μM nonessential amino acids 
at 30°C. Human adenocarcinoma (LoVo) cells were cultured in Ham’s F-12 medium 
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(Gibco) supplemented with 20% FBS, penicillin (100 U/mL), and streptomycin (100 
μg/mL). All cells except for C6/36 were maintained at 37°C and 5% CO2.
 Standard DENV2 strain 16681 was kindly provided by Dr. Claire Huang 
(Center for Disease Control and Prevention, USA). It was propagated in C6/36 cells 
as described before22. Immature (prM) DENV2 particles were produced in LoVo 
cells, as described previously86. Viral infectivity was determined by plaque assay on 
BHK-15 cells (plaque forming units, PFU)86. The absolute number of virus particles 
in solution was determined by quantitative PCR (qPCR), which detects the number 
of genome-containing particles (GCPs)29. Virus infection was performed on the 
basis of multiplicity of genome-containing particles per cell (MOG).
Antibodies
Human anti-E (mAb 5) and anti-prM (mAb 3-147) monoclonal antibodies 
were kindly provided by Gavin Screaton (Imperial College, London, UK). Purified 
anti-Mouse CD16/CD32 (Mouse BD Fc Block) was obtained from BD Biosciences. 
Convalescent human dengue immune serum (28 days following DENV2 infection) 
was generously provided by Dr. G. Comach (Biomed-UC, Lardidev, Maracay, 
Venezuela) and Dr. T. Kochel (U.S. Naval Medical Research Center Detachment, 
Lima, Peru). Mouse IgG2A Isotype Control (anti-KLH) was acquired from R&D 
Systems. Fab fragments were made from the monoclonal murine anti-E antibody 
4G2 (Millipore) by use of the Pierce™ Fab Micro Preparation Kit. 
Drugs and reagents 
 Endocytotic inhibitors such as colchicine, wortmannin, nystatin, dynasore, 
cytochalasin B, and latrunculin were purchased from Sigma Aldrich. Ammonium 
chloride (NH4Cl) was obtained from Merck and the Rac1 selective inhibitor 
NSC23766 from Tocris Bioscience. A furin-specific inhibitor, decanoyl-L-arginyl-
L-valyl-L-lysyl-L-arg inyl-chloromethylketone (decRRVKR-CMK), was obtained 
from Calbiochem. The fluorescently labeled endocytic cargos Cholera toxin B-FITC 
(CtxB-FITC), Dextran-FITC, Dextran-TxRd, and Lysotracker Green were 
purchased from Life Technologies.
Plasmids 
The GFP-tagged dominant-negative Eps15 mutant E95/295 and its empty 
vector D3Δ2 were kindly provided by Dr. A. Benmerah and Dr. A. Dautry-Varsat 
(Institute Pasteur, Paris, France). The eYFP-Actin construct (human β-actin in a 
pCDNA3.1 vector) was obtained from Dr. Ben Giepmans (UMCG, Groningen, The 
Netherlands). The Rab5-S34N-GFP dominant negative mutant (DNM) and Rab5-
wt-GFP plasmids were generously provided by Dr. P. van der Sluijs (University 
Medical Center, Utrecht, The Netherlands). The Rab7-T22N-GFP DNM and 
Rab7-wt-GFP plasmids were obtained from Gary R. Whittaker (Cornell University 





For virus-antibody complex formation, virus particles (MOG 1000 of std 
as well as prMDENV) were incubated for 30 min at 37°C in presence of serial 10-
fold dilutions of antibodies in cell culture medium containing 2% FBS. The virus-
antibody complexes were then added to 2 × 105 P388D1 cells/well, and incubated at 
37°C with 5% CO2. At 43 hours post-infection, the supernatant was collected and 
virus particle production was measured with a plaque assay. As a control, an FcR 
blocker (anti-mouse CD16/CD32) was used. The cells were pretreated with the FcR 
blocker (1 μg per 1 x 106 cells) for 10 min at 4°C before infection.
DiD-labeling of DENV
The lipophilic fluorescent probe 1,1’-dioctadecyl-3,3,3’,3’-
tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD) (Molecular 
Probes) was used to label the viral membrane of DENV virus particles, as previously 
described87, 88. When incorporated in the viral membrane at a relatively high surface 
density, the emitted fluorescence level is largely quenched, but single DiD-labeled 
virus particles can still be clearly detected. Membrane fusion is detected as an increase 
in fluorescence intensity due to dilution of the probe into the target membrane
ADE assays for DENV fusion and infection 
DiD-labeled std DENV was incubated with 400 ng/mL of mAb 5 and DiD-
labeled prMDENV with 1 ng/mL of mAb 3-147 prior to the addition to P388D1 
cells seeded in an 8-wells Lab-Tek II Chambered Coverglass (Nunc). Cells were 
then incubated for 30 min at 37°C with 5% CO2. The extent of membrane fusion of 
the DiD virus was determined with a fusion assay as described before88. Briefly, the 
P388D1 cells were washed three times and a microscopy analysis was done by taking 
15 snapshots of randomly selected fields using both differential interference contrast 
(DIC) and DiD channels. DiD-labeled viruses were detected by epi-fluorescence 
microscopy in a Leica Biosystems 6000B instrument by using a 635-nm helium–
neon laser. The acquired images were processed and analyzed with ImageJ using an 
in-house macro. The extent of membrane fusion was quantified by measuring the 
total fluorescent signal per field of view with the “Particle analyzer” plugin of ImageJ. 
The percentage of fusion inhibition was calculated with respect to the non-treated 
positive control.
Single-particle tracking of DiD-DENV
The tracking experiments were performed as previously described87. Briefly, 
P388D1 cells were seeded in 8-wells Lab-Tek II Chambered Coverglass two days 
before infection. Prior to the experiment, cells were washed three times with phenol 
red-free MEM and warm phenol red-free MEM containing 1% glucose was added. 
DiD-labeled DENV (opsonized or non-opsonized std and prMDENV) was added 
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to P388D1 cells at 37°C and kept at the same temperature throughout the tracking 
experiment. DiD-labeled DENV was detected with a 633-nm helium-neon laser. 
Image series of the fluorescent emission were recorded with a charge-coupled-device 
camera at 1 frame per s. Before and after fluorescence imaging, the localization of 
the nucleus and plasma membrane of the cell was determined by use of DIC optics. 
The acquired images were processed and analyzed with ImageJ and Imaris x64 7.6.1. 
Only those virus particles that showed more than a two-fold increase in fluorescence 
intensity after membrane fusion were used for single-particle tracking analysis. 
Trajectories were generated by pairing peaks in each frame to previously established 
trajectories according to proximity and similarity in intensity. 
Drug inhibitor studies with DiD-DENV 
Multiple endocytic inhibitors were used to define the route of DENV 
entry. The effect of the inhibitors on DENV infectivity was measured by use of a 
microscopic membrane fusion assay88. In brief, P388D1 cells were seeded in a Lab-
Tek II Chambered Coverglass (Nunc No. 155409) two days before the infection. 
The cells were washed three times and treated with the drug of interest for 1.5 h 
at 37 °C (NH4Cl, Latrunculin and EIPA treatments were done for 1 h). An end 
concentration of 50 mM NH4Cl, 50 μM nystatin, 150 μM dynasore, 15 μM 
cytochalasine B, 1 μM latrunculin, 2 μM wortmannin, 250 μM NSC23766 or 100 
μM EIPA was used. All drug dilutions were prepared in serum-free phenol red-free 
MEM (Gibco) containing 1% glucose and used at non-toxic concentrations. Then, 
DiD-labeled virus (stdDENV, Ab-stdDENV, or Ab-prMDENV) was added to the 
well in the presence of the compound at an MOG of 400. For virus-antibody complex 
formation, stdDENV and prMDENV were incubated for 30 min at 37°C with 400 
ng/mL of mAb 5 or 10 ng/mL of mAb 3-147 in serum-free media, respectively. 
The cells were then incubated 30 min at 37°C to allow virus entry. This time-point 
was chosen since 90% of the particles have fused within this timeframe (Figure 1C). 
Then, a fusion assay was performed as described in previous sections. The percentage 
of fusion inhibition was calculated with respect to the non-treated positive control.
Electroporation of P388D1 cells 
A suspension containing 3 x l06 cells (in antibiotic-free DMEM containing 
10% FBS) and 10 μg of DNA plasmid were placed in a 0.4 cm electroporation 
cuvette (Bio-Rad). The electroporation was performed at room temperature, 950 μF 
and 250 V. Afterwards, the cuvette was kept at room temperature for 4 min. The cells 
were then resuspended and seeded in an 8-wells Lab-Tek using antibiotic-free 10% 
FBS DMEM. The media was refreshed one day after electroporation. The cells were 
used for imaging on days two and three post-electroporation. 
Live-cell imaging in eYFP-Actin expressing cells




DNA per 3x106 cells) and seeded in an 8-wells Lab-Tek II Chambered Coverglass. 
At 2 days post-electroporation, the cells were washed with serum-free phenol red-
free MEM and fresh serum-free phenol red-free 1% glucose MEM was added to the 
well. Then, DiD-labeled virus (stdDENV or prMDENV) with and without prior 
antibody opsonization was added in situ in the presence or absence of the indicated 
treatments. The virus used for live-cell imaging was UV-inactivated for 1 h. UV-
treatment did not interfere with membrane fusion activity (data not shown). 
Living P388D1 cells electroporated with the eYFP-Actin construct were 
imaged with a Solamere Spinning Disk Confocal Live Cell Imaging system 
(Solamere Technology Group). This system is based on a confocal Leica DM IRE2 
Inverted microscope (Leica Microsystems) equipped with a temperature and CO2 
controlled box (Live Imaging Services). YFP and DiD fluorescence were recorded 
with a Stanford Photonics XR/Mega-10 ICCD camera (Stanford Photonics) 
using argon (488 nm) and krypton (647 nm) lasers as light sources, respectively. 
Time-lapse acquisition was done at 1 image every 4.5 seconds with a 63x objective. 
The acquired images were processed and analyzed with Imaris x64 7.6.1 (Bitplane 
Scientific Software) and ImageJ (NIH).
Immunostaining of FcgRs in P388D1 cells
Cells electroporated with eYFP-Actin construct were grown to subconfluence 
in an 8-wells Lab-Tek II Chambered Coverglass in cell culture medium. Prior to 
infection, cells were washed with PBS. At 30 min post-infection, the P388D1 cells 
were fixed with 2% paraformaldehyde (in 40 mM HEPES buffer, pH 7.2, containing 
6.8% sucrose) for 30 min at 37°C. The fixed cells were immersed in 0.25% NH4C1/
PBS for 10 min at room temperature to quench free aldehyde. Subsequently, the 
cells were permeabilized with 0.1% Triton X-IO0-2% BSA in PBS for 5 min and 
immunostained. For detection of FcγR, anti-Mouse CD16/CD32 was used as a 
primary antibody and rabbit anti-mouse Alexa647 (Life Technologies) as a secondary 
antibody. DAPI was used for nuclei staining. FcγR expression in eYFP-Actin 
positive cells was assessed by epi-fluorescence microscopy in a Leica Biosystems 
6000B instrument.
Dominant-negative mutant assays
DiD-labeled DENV was added in situ to P388D1 cells electroporated 
beforehand with the Eps15-GFP (DNM E95/295 and its empty vector D3Δ2) Rab5-
GFP (DNM S34N and WT) and Rab7-GFP (T22N DNM and WT) plasmids. A 
fusion assay was performed as described in previous sections. To assess the effect of 
the DNM on membrane fusion of the virus, 85-100 cells positive for the expression 
of the plasmid (GFP+) were the extent of membrane fusion was quantified in these 
cells as described in previous sections. The percentage of inhibition of fusion of the 
DNM was calculated with respect to the WT plasmid control. Ammonium chloride 
(50 mM) was used as a negative control (data not shown).
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Fluorescently labeled cargo controls for biochemical inhibitors and DNM
To confirm the inhibitory activity of the chemical inhibitors, different 
fluorescently labeled cargo controls were used. The activity of nystatin was confirmed 
by incubation of cells with CtxB-FITC for 30 min at 37°C. Cells treated with 
colchicine, cytochalasin B, latrunculin, wortmannin, NSC23766, and EIPA were 
incubated with Dextran-FITC for 30 min at 37°C to assess the inhibitory effect. To 
define the effect of ammonium chloride on the pH of acidic intracellular vesicles, 
P388D1 cells were stained with Lysotracker Green for 15 min at 37°C, then washed 
twice with serum-free phenol red-free MEM. Visualization was done by use of an 
epi-fluorescence Leica Biosystems 6000B microscope.
The activity of the Rab5 and Rab7 DNM plasmids was confirmed with the 
use of Dextran-TxRd. P388D1 cells were electroporated with the Rab5 or Rab7 
WT and DNM plasmids. Two days post-electroporation, the cells were treated 
with Dextran-TxRd (0.03 μg/mL) for 30 min at 37°C, washed and then imaged to 
assess Dextran uptake or co-localization. Rab5 electroporated cells were visualized 
with an epi-fluorescence Leica Biosystems 6000B microscope. To assess the effect 
of the Rab5-DNM on uptake of Dextran, 50 cells positive for the expression of the 
plasmid (GFP+) were selected and scored as positive or negative for uptake. The 
percentage of inhibition of uptake of the DNM was calculated with respect to the 
WT plasmid control. On the other hand, the activity of the Rab7-DNM was defined 
by quantifying co-localization of Dextran molecules and Rab7-GFP+ compartments. 
Since expression of the DNM form of Rab7 blocks the exit of cargo molecules from 
early to late compartments89, we quantified co-localization of Dextran molecules and 
with Rab7-WT and DNM compartments. To this end, the cells were fixed with PFA 
4% and imaged with a Leica SP8 Confocal microscope. Fifty Dextran molecules 
were assessed per condition.
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Figure S1. Anti-E and anti-prM antibodies enhance DENV infection via FcgRs. (A) 
Enhancing profile of anti-E mAb 5 complexed to stdDENV in P388D1 cells. (B) Enhancing 
profile of anti-prM mAb 3-147 complexed to prMDENV. Virus particle production was 
assessed at 43 hours post-infection by plaque assay. (C) DENV particle production in cells 
treated with and without FcR blocker. Bars represent the average of three independent 




Figure S2. Fluorescently labeled cargo controls used to confirm the activity of different 
biochemical inhibitors and Rab5 and Rab7 DNM constructs. The cargo controls were 
added to P388D1 cells upon treatment with biochemical inhibitors. (A) Lysotracker Green 
was used for ammonium chloride (50 mM), (B) Dextran-FITC for dynasore (150 μM), 
cytochalasin B (15 μM), latrunculin (1 μM), wortmannin (2 μM), NSC23766 (250 μM), 
and EIPA (100 μM), and (C) CTxB-FITC for nystatin (50 μM). Scale bar: 25 μm. (D) 
Dextran-TxRd was added to P388D1 cells after electroporation with Rab5 or Rab7 plasmids 
(GFP-tagged WT and DNM). The activity of the Rab5-DNM was assessed by quantifying 
Dextran-TxRd uptake in the DNM and WT cells. To this end, 50 cells were used of each 
condition. The percentage of inhibition of uptake of the DNM was calculated with respect 
to the WT plasmid control. (E) The activity of the Rab7-DNM was defined by quantifying 
co-localization of Dextran-TxRd molecules and Rab7-GFP+ compartments. The white 
arrowheads indicate examples of co-localization. The blue arrowheads show examples of what 
was scored as no co-localization. The graphs shows co-localization results of 50 Dextran 
molecules per condition.
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Figure S3. How to calculate the “Movement ratio” (MR). The Movement ratio quantifies 
the extent of movement of one cell over a frame sequence. To calculate it, images from 
the sequence are thresholded (binarized) to identify the pixels occupied by the cell at each 
frame. (A) The “total area” covered by the moving cell for the whole sequence is obtained 
by counting all pixels in the union of these binarized frames. (B) The area occupied by the 
cell before movement starts (smallest area) is obtained from the binarized frame with the 
smallest number of pixels. Finally, the MR in the image sequence is quantified by the ratio of 
the pixels obtained in (A) and (B), where 1 corresponds to immobility and higher numbers 
correlate with higher cell mobility. In this example, we used a sequence of 266 frames. (C) 
Overlay of the cell body outlines of the same time-lapse. The colors indicate time direction. 




Figure S4. Overlap of eYFPActin expression and DiD-labeling of cytoplasmic membrane. 
P388D1 cells electroporated with eYFP-Actin were stained with the lipophilic probe DiD for 
1 h at 37ºC. DiD was incorporated on the cell membrane. The cells were washed and imaged 
with an epi-fluorescence Leica Biosystems 6000B microscope. As shown in the figure, the 
DiD signal overlaps with eYFP-Actin.
Movie legends
Movie S1. Single-particle tracking of Ab-stdDENV particle in P388D1 cells. 
DiD-labeled stdDENV particles were opsonized with mAb5 and added in situ to 
the cells. The movie was recorded at a time-lapse of 1 frame per second using an epi-
fluorescence Leica Biosystems 6000B microscope. A sequence of 70 frames is shown. 
Membrane fusion is evident as a sudden increase in DiD fluorescence intensity. The 
images were artificially modified to show the differences in fluorescence intensity, 
from low intensity (purple) to high intensity (yellow).
Movie S2. Extensive ruffling induced by Ab-stdDENV. Actin-eYFP expressing 
P388D1 cells were infected with DiD-labeled Ab-stdDENV. The cells were then 
imaged with a Solamere Spinning Disk Confocal Live Cell Imaging system at 1 
frame per 4.5 seconds with a 63x objective. Shown is a sequence of 300 frames. For 
clarity, the DiD channel is not shown. 
Movie S3. Extensive ruffling induced by Ab-prMDENV. Actin-eYFP expressing 
P388D1 cells were infected with DiD-labeled Ab-prMDENV. Imaging was 
performed as described to the legend of Movie S2. A sequence of 400 frames is 
shown. The DiD channel is not shown for clarity purposes.
Movie S4. Mock-infected P388D1 cells. Actin-eYFP expressing P388D1 cells 
were incubated with HNE buffer and imaged as described to the legend of Movie 
S2. A sequence of 250 frames is shown. 
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Movie S5. Cells before Ab-DENV induced extensive ruffling. Actin-eYFP 
expressing cells were infected with DiD-labeled Ab-prMDENV. Imaging was 
performed as described to the legend of Movie S2. The movie shows the first minutes 
following infection.
Movie S6. Cells after Ab-DENV induced extensive ruffling. Actin-eYFP 
expressing cells were infected with DiD-labeled Ab-prMDENV. Imaging was 
performed as described to the legend of Movie S2. The movie starts at 4.5 mpi. A 
sequence of 160 frames is shown.
Movie S7. Macropinosome closure and internalization. Actin-eYFP expressing 
cells were infected with DiD-labeled Ab-stdDENV. Imaging was performed as 
described to the legend of Movie S2. A sequence of 140 frames is shown.
Movie S8. Macropinosome closure and internalization. Actin-eYFP expressing 
cells were infected with DiD-labeled Ab-stdDENV. Imaging was performed as 
described to the legend of Movie S2. A sequence of 100 frames is shown.
Movie S9. Example of Type 2 uptake. Actin-eYFP expressing P388D1 cells were 
infected with DiD-labeled Ab-prMDENV. Imaging was performed as described to 
the legend of Movie S2. A sequence of 16 frames is shown. 
Movie S10. Example of a multiple Type 2 uptake attempts to capture the virion. 
Actin-eYFP expressing P388D1 cells were infected with DiD-labeled Ab-stdDENV. 
Imaging was performed as described to the legend of Movie S2. A sequence of 300 
frames is shown.

